CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Continuous glucose monitoring (CGM)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05741489
NCT05741489N/ACompleted
CompareCT.gov

Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes

Emory University·interventional·Posted Feb 23, 2023·Updated Apr 5, 2024

In Brief

A clinical study evaluating Continuous glucose monitoring (CGM) for End Stage Kidney Disease. Completed, enrolled 40 participants across 4 sites.

Detailed Summary

Twenty participants with end stage kidney disease (ESKD) and burnt-out diabetes, and 20 non-diabetic participants with ESKD will wear a continuous glucose monitoring (CGM) device for 10 days to see if the use of CGM is a better tool to assess glycemic control than glycosylated hemoglobin (HbA1c) in patients with ESKD on dialysis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Kidney Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedFeb 23, 2023
Enrollment StartAug 10, 2022
Primary CompletionMar 9, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.4 years ago

Interventions

Continuous glucose monitoring (CGM)device

The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.